Med. praxi. 2012;9(3):124-127

Management of Adult Spasticity

doc.MUDr.Ivana Štětkářová, CSc.
Neurologická klinika 3. LF UK a FNKV Praha

We summarized modern trends in treatment of severe spasticity that worsened quality of life, mobility and self-care of disabled patients.

Spasticity is a result of lesion of pyramidal tract with loss of inhibitory influence of motor cortex on spinal motoneuron. In mild spasticity

combination of physical and pharmacological therapy and is recommended. A local administration of botulinum toxin into muscle is

suitable for focal spasticity in a small muscle group. In severe flexed spasticity of lower extremities, surgical ablation procedures may be

performed. In severe generalized spasticity intrathecal continuous baclofen delivery is a method of very successful treatment. Treatment

of spasticity is a long-term process with multidisciplinary approach.

Keywords: spasticity, pharmacotherapy of spasticity, botulinum toxin, intrathecal baclofen

Published: March 26, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Štětkářová I. Management of Adult Spasticity. Med. praxi. 2012;9(3):124-127.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Lance JW. Symposium synopsis. In: Feldman RG, Young RR, Koella WP, eds. Spasticity: disordered motor control. Chicago: Yearbook Medical 1980: 485-494.
    2. Sheen G. The pathophysiology of spasticity. European J Neurology 2002; 9: 3-9. Go to original source... Go to PubMed...
    3. Mayer NH. Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion. Muscle and Nerve 1997; (Suppl. 6): S1-13. Go to original source...
    4. Kaňovský P. Patofyziologie spasticity v dospělosti. In: Kaňovský P, Bareš M, Dufek J, a kol. (Eds). Spasticita, mechanismy, diagnostika a léčba. Maxdorf 2004: p. 83-88.
    5. Ashworth B. Preliminary trial of carisprodol in multiple sclerosis. Practitioner 1964; 192: 540-542.
    6. Bohannon RW, Smith MB. Interrater reliability of modified Ashworth scale of muscle spasticity. Phys Ther 1986; 67: 206-207. Go to original source... Go to PubMed...
    7. Snow BJ, Tsuji JKC, Bhart MH, Varelas M, Hashimoto SA, Calne DB. Treatment of spasticity with botulinum toxin: a double blind study. Ann Neurol 1990; 28: 512-515. Go to original source... Go to PubMed...
    8. Dressnandt J, Auer C, Conrad B. Influence of Baclofen upon the alpha-motoneuron in spasticity by means of F-wave analysis. Muscle Nerve 1995; 18(1): 103-107. Go to original source... Go to PubMed...
    9. Pierrot-Deseilligny E. Electrophysiological assessment of the spinal mechanisms underlying spasticity. In: Rossini PM, Mauguiere F, eds. New Trends and Advanced Techniques in Clinical Neurophysiology (EEG Suppl. 41). Elsevier Science Publishers: B.V., 1990: 264-273. Go to original source... Go to PubMed...
    10. Olvey EL, Armstrong EP, Grizzle AJ. Contemporary pharmacologic treatments for spasticity of the upper limb after stroke: a systematic review. Clin Ther 2010; 32(14): 2282-2303. Go to original source... Go to PubMed...
    11. Rosales RL, Chua-Yap AS. Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity. J Neural Transm. 2008; 115(4): 617-623. Go to original source... Go to PubMed...
    12. Ehler E, Vaňásková E, Štětkářová I. Standard komplexní léčby spasticity po cévní mozkové příhodě. Česká a slovenská neurologie a neurochirurgie 2009; 72(105): 179-181.
    13. Lazorteh Y, Sol JC, Sallerin B, Verdié JC. The surgical management of spasticity. European J Neurology 2002; 9: 35-41. Go to original source... Go to PubMed...
    14. Penn RD, Kroin JS. Intrathecal baclofen alleviates spinal cord spasticity. Lancet 1984; 1: 1078. Go to original source... Go to PubMed...
    15. Coffey R, Cahill D, Steers W. Intrathecal baclofen for intractable spasticity of spinal origin: results of a long term multicenter study. J Neurosug 1993; 78: 226-232. Go to original source... Go to PubMed...
    16. Ochs G, Naumann C, Dimitrijevic M, Sindou M. Intrathecal baclofen therapy for spinal origin spasticity. spinal cord injury, spinal cord disease, and multiple sclerosis. Neuromodulation 1999; 2(2): 108-119. Go to original source... Go to PubMed...
    17. Ordia JI, Fischer E, Adamski E, Spatz EL. Chronic intrathecal delivery of baclofen by a programmable pump for the treatment of severe spasticity. J Neurosurg 1996; 85: 452-457. Go to original source... Go to PubMed...
    18. Stempien L, Tsai T. Intrathecal baclofen pump use for spasticity: a clinical survey. Am J Phys Med Rehabil 2000; 79: 536-541. Go to original source... Go to PubMed...
    19. Stetkarova I, Yablon SA, Kofler M, Stokic DS. Procedureand device-related complications of intrathecal baclofen administration for management of adult muscle hypertonia: a review. Neurorehabil Neural Repair. 2010; 24(7): 609-619. Go to original source... Go to PubMed...
    20. Houdek M, Kala M, Pavlíček V. Míšní spasticita - nové léčebné možnosti. Praktický lékař 1996; 76: 3110-112.
    21. Medical Research Council of the UK. Aids to the Investigation of Peripheral Nerve Injuries. Memorandum No. 45. London: Pendragon House 1976: 6-7.

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.